T-1201 which IND application has been approved by US FDA and TFDA and the Phase I clinical trial has been initiated in June, 2021.

T-1201 is a small molecular drug conjugate (SMDC), exhibiting potential of multiple anti-cancer indications. The Phase I trial is to evaluate safety and tolerability of T-1201, the recommended Phase 2 dose (RP2D), and the pharmacokinetics in human, and to assess the preliminary anti-tumor activities of T-1201.

Trial information and inclusion/exclusion criteria are posted on the following website ClinicalTrials.gov: https://clinicaltrials.gov/ct2/show/NCT04866641